Aspects of the treatment of Turner syndrome.
Several issues have to be considered when taking care of girls and women with Turner syndrome. During childhood, short stature is the primary concern and treatment with growth hormone (GH) is now widely used, often in conjunction with the androgen, oxandrolone. Recent studies indicate that doses used previously in the treatment of short stature have been too small. Induction of puberty should be performed at an appropriate age with reference to the peers of the patient. In adulthood, female sex hormone substitution should be offered to possibly prevent the increased morbidity seen in Turner syndrome, which consists of increased risk of fractures and osteoporosis, a clustering of diseases like ischaemic heart disease, hypertension, stroke and Type 2 diabetes, the latter entities being involved in the insulin resistance syndrome. Furthermore, hypothyreosis are often seen and the risk of Type 1 diabetes may also be increased. Congenital malformations of the heart are frequently seen in Turner syndrome, possibly increasing the risk of dissecting aorta aneurism. Liver enzymes are often elevated in Turner syndrome and there may be an increased risk of cirrhosis of the liver. Mortality does seem to be increased in Turner syndrome and women with the 'pure' 45,X karyotype do seem to be most severely affected. In the clinical practice of Turner syndrome, a careful monitoring of glucose and bone metabolism, weight, thyroid function and blood pressure should be performed. A cardiovascular risk profile should be determined and the patient informed concerning risks and benefits from sex hormone replacement therapy. Based on the available literature, sex hormone replacement therapy is highly recommended, although at present there are no longitudinal data documenting the long-term positive effect of sex steroid substitution. However, hypogonadism is expected to explain at least part of the decreased lifespan found in Turner syndrome. Since general physicians encounter Turner patients infrequently, it is recommended that the care and treatment of Turner syndrome is centralised.
Gravholt
C H
CH
Medical Department M (Endocrinology and Diabetes) and Medcal Research Laboratories, Aarhus Kommunehospital, Aarhus University Hospital, Aarhus, Denmark. ch.gravholt@dadlnet.dk
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy; D013006:Growth Hormone / Q000627:therapeutic use; D006801:Humans; D011628:Puberty, Delayed / Q000188:drug therapy / Q000209:etiology; D014424:Turner Syndrome / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D013006:Growth Hormone